文摘
背景科目没有前一个哮喘史,出现不明原因的呼吸道症状和正常肺量测定法,可能出现(AHR)气道高反应与潜在的嗜酸性(类型2 (T2))炎症、哮喘一致。然而,哮喘的患病率在这些主题是未知的。
方法在这种观察研究,吸入corticosteroid-naive成年人没有先前诊断肺部疾病报告当前的呼吸道症状和显示正常和post-bronchodilator肺量测定法进行了分级呼出一氧化氮(F伊诺)测量、醋甲胆碱挑战测试和诱导痰分析。AHR是定义为一个挑衅的醋甲胆碱浓度导致用力呼气量下降了20%在1 s (PC20.)< 16 mg·毫升−1和T2炎症被定义为痰和/或嗜酸性粒细胞> 2%F伊诺> 25磅。
结果132名受试者(意味着±sd57.6±14.2岁,52%的女性),47 (36% (95% CI 28 - 44%))显示AHR: 20/132 (15% (95% CI 9 - 21%))与电脑20.< 4 mg·毫升−1和27/132 (21% (95% CI 14 - 28%))与电脑20.4 - 15.9 mg·毫升−1。130年的参与者来说,痰液嗜酸性粒细胞,F伊诺或两个结果,45 (35% (95% CI 27 - 43%)) T2炎症。14个参与者(11% (95% CI 6 - 16%))和PC痰嗜酸性粒细胞> 2%20.≥16 mg·毫升−1,表明嗜酸性支气管炎。T2炎症的发病率明显高于与电脑课程20.< 4 mg·毫升−1(12/20(60%)相比,那些电脑20.4 - 15.9 mg·毫升−1(8/27(30%))或≥16 mg·毫升−1(25/85 (29%)(p = 0.01)。
结论哮喘、底层T2气道炎症和嗜酸性支气管炎可能仍未确诊的高比例的主题社区中有正常的症状和post-bronchodilator肺量测定法。
文摘
哮喘和嗜酸性支气管炎可能在相当数量的受试者报告仍未确诊的呼吸道症状,但正常的肺量测定法;识别这些课程应该强调改善他们的管理http://bit.ly/3ToeCrv
脚注
作者的贡献:所有作者做出实质性贡献的概念和设计工作和解释数据,修订工作至关重要的知识内容,最终版本投稿,批准并同意负责所有方面的工作在确保相关问题的准确性或完整性的任何部分工作适当的调查和解决。帮。Boulet和e。布雷起草了手稿。
利益冲突:帮。Boulet报告赠款安进、阿斯利康、葛兰素史克、默克公司诺华和赛诺菲安万特Regeneron参与多中心研究和研究项目提出的侦探;从现时的和泰勒和弗朗西斯版税;从阿斯利康演讲费,Covis、葛兰素史克、诺华,默克公司和赛诺菲;是全球倡议大会主席哮喘(吉娜)董事会,全球哮喘组织(Interasma)持有人拉瓦尔大学的椅子在知识转移,在呼吸道和心血管健康,预防和教育和加拿大社会胸呼吸指导委员会成员。e。布雷没有披露。答:从葛兰素史克Cote报告研究经费;议长费从阿斯利康、葛兰素史克、法雷奥和赛诺菲;参与咨询委员会为葛兰素史克、阿斯利康、赛诺菲和法雷奥。 J.M. FitzGerald has attended advisory boards for GlaxoSmithKline, AstraZeneca, Novartis, Sanofi Regeneron and Theravance; received speaker fees/honoraria from AstraZeneca, GlaxoSmithKline, Sanofi Regeneron and Teva; received research funding from the NIH, Canadian Institute for Health Research, AllerGen National Centre for Excellence, GlaxoSmithKline, AstraZeneca, Sanofi Regeneron, Teva and Novartis, all paid directly to his institution; and was a member of the steering committee for the International Severe Asthma Registry, Principal Investigator for the Canadian Severe Asthma Registry, and member of the GINA Science and Executive Committees. C. Bergeron reports consulting fees from Sanofi, AstraZeneca and Takeda; payments for presentations from Grifols, AstraZeneca, Sanofi and Valeo. C. Lemière reports royalties from UptoDate; consulting fees from GlaxoSmithKline, AstraZeneca and Sanofi; payments for presentations from GlaxoSmithKline, AstraZeneca and Sanofi. M.D. Lougheed reports grants from the Manitoba Workers Compensation Board, Ontario Lung Association, Ontario Thoracic Society, Government of Ontario's Innovation Fund, Queen's University, AstraZeneca and GlaxoSmithKline; payments for co-development and co-presentation of a severe asthma preparation course from the Canadian Thoracic Society and for co-development of an accredited CME module on severe asthma from MDBriefcase; participation on advisory board for AstraZeneca; membership on the Canadian Thoracic Society Asthma Clinical Assembly and Canadian Thoracic Society Asthma Clinical Assembly Steering Committee, Health Quality Ontario's Asthma in Adults and Asthma in Children Quality Standard Advisory Committee; is past chair of the Canadian Thoracic Society Asthma Clinical Assembly, is a Canadian Thoracic Society representative on the Lung Association's board of directors and a Canadian Thoracic Society representative to the European Respiratory Society. K.L. Vandemheen has nothing to declare. S.D. Aaron reports payments for lectures from AstraZeneca, GlaxoSmithKline and Sanofi; participation on advisory boards for AstraZeneca, GlaxoSmithKline, Sanofi and Covis.
支持声明:这项工作是由渥太华医院基金会支持通过一个匿名捐赠者和加拿大健康研究所基金会(FDN格兰特154322)。资金信息,本文已沉积的Crossref资助者注册表。
- 收到了2022年7月13日。
- 接受2022年11月1日。
- 版权©2023年作者。生殖权利和权限接触权限在}{ersnet.org